126 related articles for article (PubMed ID: 12736232)
1. Strategic approach to the management of Hodgkin's disease incorporating salvage therapy with high-dose ifosfamide, etoposide and epirubicin: a Northern Region Lymphoma Group study (UK).
Proctor SJ; Jackson GH; Lennard A; Angus B; Wood K; Lucraft HL; White J; Windebank K; Taylor PR;
Ann Oncol; 2003; 14 Suppl 1():i47-50. PubMed ID: 12736232
[TBL] [Abstract][Full Text] [Related]
2. High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy.
Proctor SJ; Taylor PR; Angus B; Wood K; Lennard AL; Lucraft H; Carey PJ; Stark A; Iqbal A; Haynes A; Russel N; Leonard RC; Culligan D; Conn J; Jackson GH
Eur J Haematol Suppl; 2001 Jul; 64():28-32. PubMed ID: 11486397
[TBL] [Abstract][Full Text] [Related]
3. High dose ifosfamide in combination with etoposide and epirubicin followed by autologous stem cell transplantation in the treatment of relapsed/refractory Hodgkin's disease: a report on toxicity and efficacy.
Jackson GH; Angus B; Carey PJ; Finney RD; Galloway MJ; Goff DK; Haynes A; Lennard AL; Leonard RC; McQuaker IG; Proctor SJ; Russell N; Windebank K; Taylor PR;
Leuk Lymphoma; 2000 May; 37(5-6):561-70. PubMed ID: 11042516
[TBL] [Abstract][Full Text] [Related]
4. Ifosfamide, epirubicin, etoposide (IEV) and autologous peripheral blood progenitor cell transplant: a feasible and effective salvage treatment for lymphoid malignancies.
Clavio M; Garrone A; Pierri I; Michelis GL; Balocco M; Albarello A; Varaldo R; Canepa P; Miglino M; Ballerini F; Canepa L; Gobbi M
Oncol Rep; 2005 Oct; 14(4):933-40. PubMed ID: 16142354
[TBL] [Abstract][Full Text] [Related]
5. Dose-Modified Ifosfamide, Epirubicin, and Etoposide is a Safe and Effective Salvage Therapy with High Peripheral Blood Stem Cell Mobilization Capacity for Poorly Mobilized Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma Patients.
Fukunaga A; Hyuga M; Iwasaki M; Nakae Y; Kishimoto W; Maesako Y; Arima N
J Clin Exp Hematop; 2016; 56(1):50-4. PubMed ID: 27334858
[TBL] [Abstract][Full Text] [Related]
6. Outpatient-based ifosfamide, carboplatin and etoposide (ICE) chemotherapy in transplant-eligible patients with non-Hodgkin's lymphoma and Hodgkin's disease.
Hertzberg MS; Crombie C; Benson W; Taper J; Gottlieb D; Bradstock KF
Ann Oncol; 2003; 14 Suppl 1():i11-6. PubMed ID: 12736225
[TBL] [Abstract][Full Text] [Related]
7. Ifosfamide, epirubicin and etoposide regimen as salvage and mobilizing therapy for relapsed/refractory lymphoma patients.
Zinzani PL; Tani M; Molinari AL; Stefoni V; Zuffa E; Alinari L; Gabriele A; Bonifazi F; Salvucci M; Tura S; Baccarani M
Haematologica; 2002 Aug; 87(8):816-21. PubMed ID: 12161357
[TBL] [Abstract][Full Text] [Related]
8. Ifosfamide, epirubicin and etoposide (IEV) therapy in relapsed and refractory high-grade non-Hodgkin's lymphoma and Hodgkin's disease.
Zinzani PL; Barbieri E; Visani G; Gherlinzoni F; Perini F; Neri S; Bendandi M; Ammendolia I; Salvucci M; Babini L
Haematologica; 1994; 79(6):508-12. PubMed ID: 7534744
[TBL] [Abstract][Full Text] [Related]
9. Ifosfamide, epirubicin and etoposide (IEV) regimen as salvage and mobilization therapy for refractory or early relapsing patients with aggressive non-Hodgkin's lymphoma.
Pocali B; De Simone M; Annunziata M; Palmieri S; D'Amico MR; Copia C; Viola A; Mele G; Schiavone EM; Ferrara F
Leuk Lymphoma; 2004 Aug; 45(8):1605-9. PubMed ID: 15370212
[TBL] [Abstract][Full Text] [Related]
10. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.
Abali H; Urün Y; Oksüzoğlu B; Budakoğlu B; Yildirim N; Güler T; Ozet G; Zengin N
Cancer Invest; 2008 May; 26(4):401-6. PubMed ID: 18443961
[TBL] [Abstract][Full Text] [Related]
11. Ifosfamide- and etoposide-based chemotherapy as salvage and mobilizing regimens for poor prognosis lymphoma.
Mayer J; Vásová I; Korístek Z; Navrátil M; Klabusay M; Doubek M; Vorlícek J; Cernilová I; Vodvárka P; Petráková K
Eur J Haematol Suppl; 2001 Jul; 64():21-7. PubMed ID: 11486396
[TBL] [Abstract][Full Text] [Related]
12. Outpatient fractionated ifosfamide, carboplatin and etoposide as salvage therapy in relapsed and refractory non-Hodgkin's and Hodgkin's lymphoma.
Hertzberg MS; Crombie C; Benson W; Taper J; Gottlieb D; Bradstock KF
Ann Oncol; 2006 May; 17 Suppl 4():iv25-30. PubMed ID: 16702181
[TBL] [Abstract][Full Text] [Related]
13. Combined ifosfamide, etoposide and oxalipatin chemotherapy, a low-toxicity regimen for first-relapsed or refractory Hodgkin lymphoma after ABVD/EBVP: a prospective monocentre study on 34 patients.
Sibon D; Ertault M; Al Nawakil C; de Bazelaire C; Franchi P; Brière J; de Kerviler E; Beranger N; Thieblemont C; Brice P
Br J Haematol; 2011 Apr; 153(2):191-8. PubMed ID: 21385169
[TBL] [Abstract][Full Text] [Related]
14. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR
Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
[TBL] [Abstract][Full Text] [Related]
15. High-dose chemotherapy with carboplatin, etoposide and ifosfamide followed by autologous stem cell rescue in patients with relapsed or refractory malignant lymphomas: a phase I/II study.
Kleiner S; Kirsch A; Schwaner I; Kingreen D; Schwella N; Huhn D; Siegert W
Bone Marrow Transplant; 1997 Dec; 20(11):953-9. PubMed ID: 9422474
[TBL] [Abstract][Full Text] [Related]
16. Prolonged daily administration of oral etoposide in lymphoma following prior therapy with adriamycin, an ifosfamide-containing salvage combination, and intravenous etoposide.
Haim N; Ben-Shahar M; Epelbaum R
Cancer Chemother Pharmacol; 1995; 36(4):352-5. PubMed ID: 7543029
[TBL] [Abstract][Full Text] [Related]
17. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
18. Ifosfamide, epirubicin and etoposide (IEV) in non-Hodgkin's lymphoma and Hodgkin's disease: the Italian experience.
Zinzani PL
Ann Oncol; 2003; 14 Suppl 1():i43-5. PubMed ID: 12736231
[No Abstract] [Full Text] [Related]
19. Toxicity and efficacy of ifosfamide, carboplatin and etoposide (modified ICE) as a salvage chemotherapy in Japanese patients with relapsed or refractory aggressive non-Hodgkin's lymphoma.
Itoh K; Igarashi T; Ohtsu T; Wakita H; Watanabe Y; Fujii H; Minami H; Sasaki Y
Int J Hematol; 1998 Dec; 68(4):431-7. PubMed ID: 9885442
[TBL] [Abstract][Full Text] [Related]
20. Ifosphamide, etoposide and epirubicin is an effective combined salvage and peripheral blood stem cell mobilisation regimen for transplant-eligible patients with non-Hodgkin lymphoma and Hodgkin disease.
Bishton MJ; Lush RJ; Byrne JL; Russell NH; Shaw BE; Haynes AP
Br J Haematol; 2007 Mar; 136(5):752-61. PubMed ID: 17313378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
